Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 55
- Registration Number
- NCT01029730
- Locations
- 🇺🇸
Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸Hematology Oncology of the North Shore, Skokie, Illinois, United States
🇺🇸Holy Cross Hospital, Ft. Lauderdale, Florida, United States
A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT01028313
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
- First Posted Date
- 2009-12-08
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 202
- Registration Number
- NCT01027598
- Locations
- 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT01014351
- Locations
- 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Oncology Hematology of SW Indiana, Evansville, Indiana, United States
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00972335
- Locations
- 🇺🇸
Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
🇺🇸Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
SCRI Tissue Testing Registry
- Conditions
- Interventions
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00965861
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT00960297
- Locations
- 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Providence Medical Group, Terre Haute, Indiana, United States
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 113
- Registration Number
- NCT00915603
- Locations
- 🇺🇸
Wilshire Oncology Medical Group, LaVerne, California, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
🇺🇸Aventura Medical Center, Aventura, Florida, United States
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT00906282
- Locations
- 🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT00894504
- Locations
- 🇺🇸
Family Cancer Center, Collierville, Tennessee, United States
🇺🇸Los Robles, Thousand Oaks, California, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States